Kornimate/medical-research-clean huggingface dataset:
melanoma perception and health literacy in people of color

Conditions: Melanoma

Summary: this study will examine the effectiveness of a targeted, health literate educational intervention for people of color compared to a standard melanoma education pamphlet for increasing knowledge and promoting early melanoma detection. it is hypothesized that people of color are less aware of their risk for developing melanoma and that a targeted educational intervention will help increase knowledge and promote early melanoma detection especially in individuals with low health literacy.

this targeted educational intervention will compare a standard melanoma education pamphlet with one that has been modified to target people of color. both pamphlets will include the abcdes of melanoma, risk factors, prevention and treatment. in addition, the targeted pamphlet will incorporate the recommendations made by people of color in previous studies. the pamphlets will be randomized to subjects at a study visit along with a health literacy test and a questionnaire aimed at determining subjects' baseline melanoma knowledge and current melanoma prevention practices. 2 months post-intervention, a follow-up phone call will be made to assess subject knowledge retention and behavior change.

Eligibility criteria:
inclusion criteria: * english-speaking * self-identifies with one of the following races/ethnicities: african american, asian/pacific islander, american indian and alaskan native, or hispanic exclusion criteria: * not proficient in english * unable to give informed consent * does not self-identify with the following races/ethnicities: african american, asian/pacific islander, american indian and alaskan native, or hispanic

Keywords: melanoma people of color
comparing surgical decompression versus conservative treatment in incomplete spinal cord injury

Conditions: Central Spinal Cord Syndrome

Summary: traumatic central cord syndrome (tccs) was until recent recognized as a separate clinical entity. the most characteristic feature is the disproportionate more motor impairment of the arms and especially the hands than the legs, bladder dysfunction and sensory. recently, it has been shown that the distinction of tccs with an incomplete cervical spinal cord lesion (icscl) is artificial. it is the most frequent incomplete traumatic spinal cord lesion. it accounts for up to 70 % of all incomplete cervical spinal cord lesions. the exact incidence is not known. uncertainty about the treatment exists. a good recovery has been described after conservative treatment. conservative treatment was usually considered when a fracture or dislocation of the spine were absent. it is often seen in hyperextension trauma in the elderly with degenerative spondylotic stenotic cervical spine. however, some reports suggest a better outcome after surgical decompression. randomized trials have not been performed. to avoid discussion about possible confounding or effect modification related to the mechanism of trauma, this study will focus on icscl in patients without fracture or instability of the cervical spine on radiological examination. also the problem of crossover from the conservative group to the surgical one due to the nature of spinal instability will be reduced. goal of the study: to compare the efficacy of early decompressive surgery to improve functional outcome in patients with icscl without a fracture or instability of the cervical spine compared to those receiving conservative treatment. definition of icscl in this study: icscl is an incomplete spinal cord lesion due to a cervical spine trauma. at ct scanning with reconstruction and at mri signs are not seen that could indicate a fracture of the cervical spine or instability. an overt sequestrated herniated disc should not be present since this will always necessitate immediate surgery. involvement of the cervical spinal cord should be established at physical examination (symptomatic arm or hand dysfunction is obligatory).

see above. further information in this registration ( randomized controlled trial (rct), sample size etc)

Eligibility criteria:
inclusion criteria: - all patients with a history of a traumatic event to the cervical spine fulfilling the criteria of incomplete cervical spinal cord lesion. - exclusion criteria: * cognitive impairments * a preexistent neurologic deficit of arms and/or legs * psychiatric illness * significant comorbidity interfering with the indication to perform surgery or not * use of anticoagulating drugs * addiction to drugs or alcohol (more than five units daily) * not speaking dutch language fluently * not willing to participate * participating in another trial

Keywords: surgical decompression conservative treatment incomplete spinal cord lesion recovery
codeine on pharyngeal and esophageal motility

Conditions: Esophageal Motility Disorders

Summary: opioids act on opioid receptors located in the brain as well as in the gastrointestinal (gi) tract to induce changes in motility. a variety of studies have linked chronic opioid use with changes in intestinal and to a lesser extent esophageal motility. less is known about acute administration effects on distal esophageal motility and les and even less with respect to proximal esophagus, ues and pharynx. codeine, an opioid receptor agonist, by acting both centrally as well as in the periphery may induce changes in parts of the gi tract implicated in deglutition. therefore, to evaluate the hypothesis the researchers will study motility patterns in the pharynx, ues, proximal and distal esophagus and les in 22 healthy volunteers receiving placebo or codeine (60 mg) in a double-blind randomized cross-over controlled fashion. motility patterns will be studied using state-of-the-art criteria and analytic tools (chicago 3.0, aimplot analysis).


Eligibility criteria:
inclusion criteria: * healthy volunteers aged between 18-60 years old * written informed consent exclusion criteria: * no chronic disease/medication * no gi symptoms * not pregnant or breast-feeding * no history of head/neck surgery * not allergic to codeine

Keywords: codeine esophageal motility pharyngeal motility
safety of metformin in pregnancy

Conditions: Pregnancy; Pregestational Diabetes; Polycystic Ovary Syndrom

Summary: this study aims to better characterize the risk linked to metformin use during pregnancy, using a prospective multicentric cohort design enabling a large sample size, in evaluating the rate of birth defects after first trimester exposure, as well as several other pregnancy related outcomes.


Eligibility criteria:
inclusion criteria: * exposed group: exposed to metformin (anatomical therapeutic chemical a10ba02) any time during pregnancy (i. e. any time from conception to week 42 after last menstrual period (lmp)). * reference group: at no time during pregnancy were exposed to metformin, insulin or any other hypoglycaemic agent. exclusion criteria: * exposed to any of the following known major teratogen or major fetotoxicant: acitretin, isotretinoin, mycophenolate, thalidomide, valproic acid, angiotensin-ii receptor blockers (only when used in 2nd or 3rd trimester), ace inhibitors (only when used in 2nd or 3rd trimester), or (b) following treatment indications coded: malignancies (meddra code: malignant or unspecified tumors (smq 20000091), icd-10: c00-d09)) or malignancy related conditions (meddra: smq 20000092), icd-10: c00-d09). * lost to follow-up

Keywords: metformin pregnancy outcomes birth defects spontaneous abortion pharmacoepidemiology
ecmm candida registry - candireg

Conditions: Invasive Candidiases

Summary: the objective of the european confederation of medical mycology - ecmm candida registry (candireg) is to overcome the lack of knowledge on epidemiology, clinical course, and molecular characteristics of invasive infections due to invasive candida infections and to function as a platform for future studies and in case of outbreaks.

the specific objectives are: to describe the global incidence of invasive candida infection to monitor trends globally and locally over time to define patient risk groups to assess antifungal resistance among candida spp. causing invasive diseases worldwide to assess attributable mortality of invasive candida infection to assess incremental costs associated with invasive candida infection to describe the clinical pattern of disease to document diagnostic procedures performed for confirmation of diagnosis to describe first-line and salvage treatment regimens applied, guideline adherence, their efficacy and impact on patient survival to inform consensus guidelines to develop clinical screening and diagnostic procedures set up of a collection of isolates with molecular characterization and evaluation of resistance genes

Eligibility criteria:
inclusion criteria: * cultural, histopathological, antigen or dna evidence of invasive fungal infection with candida species. * hepatosplenic candidiasis with signs of disseminated candida infection without culture, histological or microscopic evidence * case control matching procedure for controls: in part, controls will be included at the same hospitals that include cases (i.e. each one control per case, both in the same hospital). controls will be matched by demographics, underlying diseases and risk factors as well as duration of hospitalization exclusion criteria: - colonization or other non-invasive infection, including superficial skin infections, candiduria without dissemination or candida spp. in stool.
covid-19 associated with psoriasis

Conditions: Psoriasis Patients; COVID-19

Summary: a retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.

based on the patients registered in the psoriasis patient database of each center, the patients were followed up by telephone, and the severity of covid-19 infection, the change of psoriasis condition and the adjustment of treatment methods of psoriasis patients were collected for retrospective analysis.

Eligibility criteria:
inclusion criteria ---- 1. no age limit, both male and female are accepted; 2. psoriasis patients registered in the database; 3. patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided. exclusion criteria ---- patients are thought having conditions which are not appropriated for attending this clinical trial.

Keywords: psoriasis covid-19
near infrared fluorescence imaging for bladder cancer detection

Conditions: Bladder Cancer

Summary: the primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate hcl avid tumors using protoporphyrin ix (ppix) near infrared fluorescence (nirf).


Eligibility criteria:
inclusion criteria: * diagnosis of bladder mass on office cystoscopy suspicious for malignancy, either newly diagnosed or a recurrent tumor. * planned transurethral resection of bladder tumor in the operating room. * ability to give informed consent. * willing to spend time for the study * men or women (age 18 or older) * any racial or ethnic origin exclusion criteria: * pregnancy * nursing mother * diagnosis of porphyria * gross hematuria * bcg immunotherapy or intravesical chemotherapy within the past 90 days * known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid
topical gel anti-fungal agent for tinea unguium

Conditions: Onychomycosis

Summary: the purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis). the formulation used as the vehicle for the active agents has been shown in earlier studies to facilitate the penetration of the active agent through fungally-infected nails. this study will examine dose-response and agent differences in terms of efficacy and safety. once the subject has qualified for the study, he/she will be randomly assigned to one of five study groups, dispensed appropriate study medication and instructed to apply one drop to the great toe designated for study.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of distal subungual tinuea unguium of one great toenail. * between 20 - 65% infected area for target nail * 2 mm of clear nail proximally on target nail * positive dermatophyte culture and positive koh test * able to sign informed consent * understand requirements of study * females must be post-menopausal or agree to use approved contraceptives throughout the study exclusion criteria: * patients with nails infected with organisms other than dermatophytes * patients with proximal subungual tinea unguium * patients with spikes of disease extending to nail matrix * patients with more than 5 infected nails * patients with confounding problems/ abnormalities of target nail * patients with screening lab values more than 20% of normal * patients with known hypersensitivity to test material components * patients requiring systemic medications that may interfere with study * patients with a poor history of compliance with study requirements

Keywords: tinea unguium onychomycosis
safety and efficacy study of xyrem® (sodium oxybate) in subjects with fibromyalgia.

Conditions: Fibromyalgia

Summary: the objective of this trial is to evaluate the safety and efficacy of xyrem® in long term use.

the trial is an open-label safety and efficacy study of subjects with fibromyalgia who completed either study 06-008 or 06-009. total duration is up to 40 weeks of trial participation.

Eligibility criteria:
inclusion criteria: * subject has qualified for and completed either study 06-009 (nct00423813) or 06-008 (nct00371137). * subject is able, in the opinion of the investigator, to take xyrem® for approximately 9-1/2 months. exclusion criteria: * subject terminated early from either study 06-009 or 06-008. * subject experienced any serious adverse event related to study drug in either study 06-009 or 06-008. * subject, in the opinion of the investigator, experienced an adverse event in 06-009 or 06-008 that may prevent him/her from safely participating in this study.

Keywords: fms fibro pain body pain tenderness joint pain stiffness muscular pain
applicability of pdox in patients with primary liver cancer: a randomized controlled trial

Conditions: Hepatocellular Carcinoma Resectable

Summary: this randomized controlled trial was to clarity the clinical feasibility of pdox results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

data of patients who received pdox after primary liver cancer radical reaction and received transarterial chemoembolization #will be collected #excluding incomplete data. the primary endpoint was the one-year disease-free survival(dfs) rate #secondary endpoint was the adverse event.

Eligibility criteria:
inclusion criteria: 1. undergone radical surgical resection. 2. aged 18-75. 3. patients voluntarily cooperated with the study and signed an informed consent form. 4. histopathologically diagnosed hepatocellular carcinoma. 5. patients with r0 resection confirmed by imaging and pathology (no residual lesions and complete tumor resection after radical surgery). 6. child-pugh score of 5-7 (a or b), patients with a score of 7 must be free of ascites. 7. ecog physical fitness status score of 0-1. 8. no serious heart, lung, or renal dysfunction exclusion criteria: 1. unable to provide specimens for pdox testing. 2. patients with recurrent liver cancer. 3. developing two or more types of tumors simultaneously. 4. patients with existing extrahepatic distant metastases. 5. treatment with other experimental drugs or other interventions after radical resection. 6. patients with other malignant tumors that have not been cured within 5 years. 7. patients with non-radical resections (r1 and r2 resections). 8. patients with residual or recurrent lesions detected on imaging within 1-2 months after surgery. 9. died within 1 month after surgery.
spermatogonial stem cell (ssc) transplant and testicular tissue grafting

Conditions: Infertility, Male; Cancer; Autoimmune Disorder

Summary: spermatogonial stem cell transplantation through ultrasound guided rete testis injection and testicular tissue grafting will be performed for participants who have frozen testicular tissue prior to gonadotoxic therapy. the purpose of this study is to test the safety and feasibility of these transplant technologies and restore fertility for these participants.

azoospermia (no sperm in ejaculated semen) impacts 1% of men in the general population and 15% of infertile men, which translates to 645,000 males between the ages of 20 and 50 (prime reproductive years) in the united states. spermatogenesis arises from a population of spermatogonial stem cells in the testes that maintain continuous sperm production throughout a man's post-pubertal life. diseases or medical treatments that compromise the stem cell pool and/or prevent the stem cells from differentiating can cause infertility. adult men have the option to cryopreserve a semen sample prior to therapy but this is not an option for prepubertal patients who are not yet producing sperm. this study will test the safety and feasibility of two approaches to restore sperm production using previously cryopreserved testicular tissues, which contain spermatogonial stem cells. the first approach is autologous transplantation of testicular cells, including spermatogonial stem cells, into the testis using ultrasound-guided rete testis injection. the second approach is autologous grafting of intact pieces of testicular tissue under the skin in the scrotum.

Eligibility criteria:
inclusion criteria: * male participant at least in tanner stage 3 * previously cryopreserved and stored testicular tissue/cells (frozen due to an infertility-risking diagnosis or treatment such as chemotherapy or radiation) available for autologous transplantation and grafting * healthy enough to undergo anesthesia * written clearance for the procedure from the patient's hematologist or oncologist to confirm the patient has finished treatment for primary condition and are clear to undergo autologous stem cell transplant exclusion criteria: * participants considered to be high risk for surgical complications * participants with a history of leukemia, lymphoma or testicular cancer or a cancer that likely involved testicles at the time of testicular tissue collection * diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent.

Keywords: spermatogonial stem cells testis fertility oncofertility
mucosal immunity in terms of sars-cov-2 antibodies in saliva after covid-19 infection and vaccination

Conditions: Covid19

Summary: the primary objective of this single-center study is to investigate the sars-cov-2 spike glycoprotein rbd antibody concentration in saliva and serum in healthy non vaccinated and non-sars-cov-2 infected, covid-19 convalescents, persons vaccinated with pfizer-biontech bnt162b2, moderna mrna-1273 or astrazeneca chadox1 ncov-19 azd1222 vaccines, and convalescent covid-19 patients that have subsequently been vaccinated. a potential difference in the immunoglobulin concentrations of the pfizer-biontech bnt162b2 vaccine, moderna mrna-1273 vaccine and the astrazeneca chadox1-s vaccine will be uncovered. this knowledge about the mucosal immunity will be important for further designing of vaccine strategies.


Eligibility criteria:
inclusion criteria: * written informed consent * both hospital staff as well as non-health care workers will be invited to participate exclusion criteria: * individuals not fulfilling the inclusion criteria or declining blood or saliva collection. * exclusion criteria are neck breathers (tracheostomy/laryngectomy patients) or other nasopharyngeal or oropharyngeal anomalies that do not allow for sampling using salivette.

Keywords: sars-cov-2 antibodies saliva mucosal immunity vaccination covid19 spike glycoprotein
benefits of an aerobic and strength rehabilitation program with post- sars-cov-2 patients moderate-severe

Conditions: COVID-19

Summary: the sars-cov-2 is a pulmonary pathology which is caused by sars-cov2 and the main signs and symptoms are fever, dyspnea, cough, fatigue, muscular pain and more. even if sars-cov-2 is an acute respiratory pathology we know that can cause some chronic conditions in the general status health of the patients. besides, it can have an important impact in the physique condition such as a detrimental of the aerobic capacity, lung capacity based on the severity of the patient. on the other hand, world health organization (who) has a criteria to classify the severity of sars-cov-2; saturation de o2 \<94%, pao2/fio2: \<300mm frecuencia respiratoria \> 30p/m abscess lung \> 50% septic shock multiorganic failure based on the high survival but the important number of side effects of this pathology remaining the detrimental of the health and exercise condition. we justify our study based on an aerobic exercise program with a strength part to improve those conditions of the patients.

the investigators develop an aerobic exercise program for two treatment groups which one of them has a strength program as a supplement to verify if the aerobic exercise plus strength improve more than aerobic exercise alone the condition of covid patients. the protocol is based on 8 weeks of program with a baseline measurements and a follow ups after the 8º weeks, at 2, 4 and six months after finish the treatment to compare the effectiveness of both treatment and between them.

Eligibility criteria:
inclusion criteria: * patients had been got covid in the last 2 years. * no fractures, or major injuries which could compromised the movements of the patient * no major pathologies which deteriorate the general health status exclusion criteria: * psychiatric (moderate to severe) * acute infection * fractures (moderate to severe) * cognitive detrimental state

Keywords: rehabilitation covid strenght exercise aerobic program
endoscopic common bile duct stones clearance during pregnancy

Conditions: Common Bile Duct Calculi

Summary: background: pregnancy is associated with a higher risk of common bile duct stones. currently endoscopic retrograde cholangiopancreatography (ercp) is the treatment of choice for symptomatic choledocholithiasis. however, ercp during pregnancy is associated with hazards of radiation exposure, as well as challenging patient positioning and anesthesia

this is a retrospective analysis of endoscopic common bile duct stone clearance in pregnant patients with symptomatic choledocholithiasis between june 2015 and june 2023. sedation and anesthesia was done by safe medications by senior anesthetist, and the endoscopic procedure was performed in left lateral decubitus instead of prone position. the gravid uterus was kept away from the monopolar electrocautery current pathway. radiocontrast injection and fluoroscopy was deleted and replaced by trans-abdominal us and endoscopic bile aspiration data including perioperative outcomes and follow up data will collected, tabulated and analyzed.

Eligibility criteria:
inclusion criteria: * pregnant women with symptomatic common bile duct stones. exclusion criteria: * presence of pancreatitis or cholangitis.

Keywords: common bile duct stones endoscopic clearance jaundice pregnancy